Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.

Transplant international : official journal of the European Society for Organ Transplantation - 1 Dec 2016

Rostaing Lionel, Alric Laurent, Kamar Nassim

Abstract excerpt

In some parts of the world, hepatitis C virus (HCV) infection remains a huge problem for kidney transplant candidates and kidney transplant (KT) recipients. Until 2 years ago, anti-HCV treatment for the general population relied on pegylated alpha-interferon plus ribavirin, but led to a sustained viral response (SVR) in <50% of cases. This treatment was contraindicated in KT patients because of acute-rejection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Benzofurans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Cyclopropanes

Share to Imidazoles

Share to Kidney Failure, Chronic

Share to Quinoxalines

Share to Transplant Recipients

Source

Identifiers

PMID: 27717014
DOI: 10.1111/tri.12870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.PMID 27717014Read ↗

Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.Semantic proximity Read ↗

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.Semantic proximity Read ↗

Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational StudySemantic proximity Read ↗

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.Semantic proximity Read ↗

Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.Semantic proximity Read ↗

Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.